<a href=AstraZeneca‘s Alderley Park R&D site” height=”248″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/static-progressive/az-alderley.jpg” style=”padding: 10px” width=”300″ />

Job cuts at Anglo-Swedish pharmaceutical firm AstraZeneca (AZ) are to be worse than feared, following an announcement made by the company amid rumours previously reported in the Sunday Times.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Sunday Times originally reported that up to 3,000 jobs could go, but AZ has now revealed that a total of 7,300 jobs will be cut over the next two years as part of an extensive restructuring programme.

The announcement comes against a backdrop of disappointing financial results, with the company reporting a fall in pre-tax profits for the quarter ending December 2011, down $230m to $2.05bn, for which AZ has blamed increased competition.

Amidst increased generic competition for some of its products, AZ must also contend with the looming patent expiry of its cholesterol drug Crestor, which loses exclusivity in 2016.

See Also:

AstraZeneca has previous for extensive rounds of job cuts, with its first round of restructuring occurring between 2007 and 2009, resulting in the loss of 12,600 positions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A further 9,000 jobs were announced to be lost in the company’s second restructuring programme, taking place between 2010 and 2012. The latest round is expected to save up to $1.6bn per year by 2014.

AstraZeneca, the UK’s second largest drugs firm behind GlaxoSmithKline, currently employs 61,000 staff globally.

 

Caption: Up to 300 job losses could be seen at AstraZeneca’s Alderley Park R&D site, pictured. Credit: AstraZeneca